Pharmaceutical (non-cosmetic)
Thalidomide (INN) and its salts
Safety score · 0–100
Not Rated
Derived from EU CosIng regulatory status, PubChem hazard data and published research. How we score.
Thalidomide — the notorious teratogen behind one of the worst drug disasters in history. Prohibited in cosmetics under EU Annex II with no permissible use.
Thalidomide (CAS 50-35-1) is an immunomodulatory pharmaceutical best known for causing phocomelia and other severe congenital defects in an estimated 10,000-20,000 children whose mothers took it as a morning-sickness remedy in the late 1950s and early 1960s. Under CLP Regulation (EC) No 1272/2008 it is classified as H360 (may damage fertility or the unborn child) and H302 (harmful if swallowed). It is listed in Annex II of EU Regulation (EC) No 1223/2009 (Cosmetics Regulation), which prohibits its presence in cosmetic products under any circumstances. Medical use today (e.g., multiple myeloma, leprosy reactions) is tightly controlled through risk-evaluation programs like REMS. There is no legitimate cosmetic formulation, concentration, or delivery system for thalidomide.
Skin benefits
- Has no legitimate role as a cosmetic ingredient
Known concerns
- Severe teratogen
- EU Annex II — prohibited
- GHS H360/H302
- Cosmetic presence indicates adulteration
References
EU CosIng database
European Commission cosmetic ingredient registry: regulatory status, restrictions, authorised functions.
Related pharmaceutical (non-cosmetic)s
Check your shelf
Find Thalidomide (INN) and its salts in your products.
Scan any cosmetic product with LuxSense to see if it contains Thalidomide (INN) and its salts and get a full ingredient breakdown with safety scores.
This profile is for educational purposes and does not constitute medical advice. Regulatory status and scientific understanding evolve, so always read the physical product label and consult a healthcare professional for personal concerns.